Exodus Point Capital Management, LP Arcus Biosciences, Inc. Transaction History
Exodus Point Capital Management, LP
- $14.7 Billion
- Q2 2024
A detailed history of Exodus Point Capital Management, LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 58,951 shares of RCUS stock, worth $908,434. This represents 0.01% of its overall portfolio holdings.
Number of Shares
58,951Holding current value
$908,434% of portfolio
0.01%Shares
14 transactions
Others Institutions Holding RCUS
# of Institutions
207Shares Held
49MCall Options Held
173KPut Options Held
151K-
Black Rock Inc. New York, NY9.76MShares$150 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$81 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA4.25MShares$65.4 Million0.65% of portfolio
-
State Street Corp Boston, MA3.06MShares$47.1 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.83MShares$28.3 Million0.08% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.11B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...